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OBJECTIVES The objective of this study was to confirm that the efficacy and safety of percutaneous
coronary intervention (PCI) in diabetic patients are not compromised by a bivalirudin-based
antithrombotic strategy.
BACKGROUND Previous studies have shown a survival benefit with use of platelet glycoprotein (GP) IIb/IIIa
inhibitors in diabetic patients undergoing PCI. The Randomized Evaluation in Percutaneous
Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial
showed the non-inferiority of a strategy of bivalirudin with provisional GP IIb/IIIa inhibition
compared with routine GP IIb/IIIa inhibition. The relative efficacy of these two strategies in
diabetic patients has not been studied.
METHODS We evaluated the diabetic patients enrolled in the REPLACE-2 trial to assess the impact of
these antithrombotic strategies on the short- and long-term outcome after PCI.
RESULTS The REPLACE-2 trial enrolled 1,624 diabetic patients and 4,368 non-diabetic patients.
Compared with non-diabetic patients, diabetic patients had similar short-term outcome but
higher mortality at 1 year (3.06% vs. 1.85%, p  0.004). There was no difference in
short-term or long-term ischemic events among the diabetic patients randomized to the two
arms. Specifically, the 1-year mortality rate was non-significantly lower in the bivalirudin arm,
suggesting no differential survival impact of the two strategies (2.3% vs. 3.9%). There was less
minor bleeding in the bivalirudin arm in diabetic patients (12.6% vs. 24.4%, p  0.001),
whereas no difference was seen in the incidence of major bleeding (3.0% vs. 3.3%, p  0.69).
CONCLUSIONS Compared with routine GP IIb/IIIa inhibition, the use of bivalirudin with provisional GP
IIb/IIIa inhibitors in diabetic patients is associated with no differences in clinical outcomes at
30 days, a trend toward lesser mortality at 1 year, and a reduction in minor bleeding. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.074Coll Cardiol 2005;45:1932–8) © 2005 by the American College of Cardiology Foundation
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Giabetic patients are more prone to developing atheroscle-
osis (1) and generally have a worse long-term outcome after
ercutaneous coronary intervention (PCI) compared with
on-diabetic patients. Previous studies have suggested that
latelet glycoprotein (GP) IIb/IIIa inhibitors have an en-
anced benefit in diabetic patients undergoing PCI (2) for
cute coronary syndromes. A retrospective pooled analysis
rom three trials of abciximab had shown that use of
From the *Cleveland Clinic Foundation, Cleveland, Ohio; †University of Virginia
ealth Systems, Charlottesville, Virginia; ‡The Lindner Center and The Ohio Heart
ealth Center, Cincinnati, Ohio; §Duke Clinical Research Institute, Durham, North
arolina; Methodist-DeBakey Heart Center and Baylor College of Medicine,
ouston, Texas; ¶New York University School of Medicine, New York, New York;
Oscala Heart Institute, Munroe Regional Medical Center, Oscala, Florida; and
he **University Hospital Nottingham, Nottingham, United Kingdom. The
EPLACE-2 trial was funded by a grant from the Medicines Company, Parsippany,
ew Jersey.e
Manuscript received January 6, 2005; revised manuscript received February 17,
005, accepted February 21, 2005.bciximab may be associated with a one-year survival
dvantage among diabetic patients (3).
Based on this line of evidence, the use of GP IIb/IIIa
nhibitors has been strongly advocated for diabetic patients
ndergoing PCI. The GP IIb/IIIa inhibitors, although useful
or reducing peri-procedural events, are associated with an
ncreased hazard of bleeding. Recently the Randomized Eval-
ation in PCI Linking Angiomax to Reduced Clinical Events
REPLACE)-2 study showed that bivalirudin with provisional
P IIb/IIIa inhibition is not inferior to heparin plus GP
Ib/IIIa inhibition in patients undergoing elective or urgent
CI (4).Given the benefits of GP IIb/IIIa inhibitors in
iabetic patients, however, it is important to confirm that the
fficacy and safety of PCI in this population are not compro-
ised by a bivalirudin-based antithrombotic strategy in which
P IIb/IIIa inhibitors are used only selectively.
Therefore, we evaluated the subgroup of diabetic patientsnrolled in the REPLACE-2 trial to assess whether there
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June 21, 2005:1932–8 Diabetic Patients in the REPLACE-2 Trialas a difference in the short- or long-term outcome with the
se of the two anticoagulation strategies. Further, we
ompared the outcomes of diabetic and non-diabetic pa-
ients to assess whether advances in medical care have
meliorated the high-risk profile associated with diabetes
fter percutaneous coronary revascularization.
ETHODS
he design and results of the REPLACE-2 trial have been
reviously published (4). This trial randomized 6,010 pa-
ients undergoing elective or urgent PCI to either bivaliru-
in (0.75 mg/kg bolus and 1.75 mg/kg/h infusion) and
rovisional GP IIb/IIIa inhibitor or to heparin (65 U/kg
olus) and planned GP IIb/IIIa inhibition in a double-blind
ashion. All patients received aspirin. Clopidogrel pretreat-
ent was strongly encouraged, and all patients were treated
ith aspirin and clopidogrel for 30 days after PCI. Provi-
ional GP IIb/IIIa inhibition (with an agent selected by the
perator before the procedure or placebo if the patient was
n the heparin and routine GP IIb/IIIa inhibitor arm) could
e provided during the PCI at any time at the discretion of
he operator for abrupt closure, flow-limiting dissection,
ide-branch closure, distal embolization, slow flow, or any
ther clinical or angiographic instability.
The primary end point was the composite of death,
yocardial infarction, ischemia requiring urgent revascular-
zation, or in-hospital major bleeding within 30 days.
yocardial infarction was centrally adjudicated by an inde-
endent panel and was defined as either: 1) creatine kinase
r creatine kinase-myocardial band elevation 3 times the
pper limit of normal if within two days of revasculariza-
ion, or2 times the upper limit of normal if not associated
ith revascularization; or 2) by new Q waves in two or more
djacent electrocardiographic leads. Major bleeding was
onsidered to have occurred if any of the following defini-
ions was satisfied: a hemoglobin decrease 4 g/dl; overt
leeding with hemoglobin decrease 3 g/dl; two or more
nits of blood transfused; or retroperitoneal, intraocular, or
ntracranial hemorrhage. Minor bleeding was defined as
vert bleeding not meeting the criteria for major bleeding.
The trial excluded patients undergoing PCI as reperfu-
ion therapy for acute myocardial infarction. Patients were
lso excluded if they required ongoing warfarin therapy or
ad been treated with unfractionated heparin within 6 h
unless the activated partial thromboplastin time was 50
Abbreviations and Acronyms
GP  glycoprotein
PCI  percutaneous coronary intervention
REPLACE-2  Randomized Evaluation in Percutaneous
Coronary Intervention Linking
Angiomax to Reduced Clinical Events
trial), low-molecular-weight heparin within 8 h, bivalirudin dithin 24 h, abciximab within 7 days, or eptifibatide or
irofiban within 12 h before randomization.
Diabetes was defined by patient report, the treating
hysician, or both. One-year follow-up was based on
elephone contact and was obtained beyond 270 days in 98%
f the cohort.
tatistical analysis. Baseline characteristics were summa-
ized by the use of frequencies and percentages for categor-
cal variables and means and standard deviation for contin-
ous factors. Differences in baseline characteristics were
ested with Pearson chi-square tests for categorical variables,
ilcoxon rank sum test for creatinine clearance, and acti-
ated clotting time and unpaired t test for age and weight.
ne-year event-free survival was illustrated with Kaplan-
eier curves, and outcomes were compared using the
og-rank test. All analysis was intention to treat. A p value
f  0.05 was used as the level for statistical significance.
he statistical software used was SAS version 8.0 (SAS Inc,
ary, North Carolina).
ESULTS
iabetic status and outcome. The REPLACE-2 trial
nrolled 1,624 diabetic patients and 4,368 non-diabetic
atients (Table 1). The diabetic patients were more likely to
e older, to have greater body weight, and to be female and
inority patients. They were more likely to have had
ndergone prior coronary revascularization and to have
ypertension or congestive heart failure. Conversely, they
ere less likely to be current or past smokers. Diabetic
atients more frequently underwent multivessel and saphe-
ous bypass graft interventions.
Table 2 describes the outcome of the entire population by
iabetic status. Provisional therapy was used in 272 (6.2%)
on-diabetic patients and 101 (6.2%) diabetic patients (p 
.99). There was no difference in 30-day mortality between
he two groups, whereas the incidence of myocardial infarc-
ion and urgent revascularization was greater in the non-
iabetic population. Compared with non-diabetic patients,
he diabetic patients were more likely to undergo target
essel revascularization by six months. At one year, there
ere 128 deaths in the entire cohort. Despite a seemingly
etter or equivalent early outcome, diabetic patients had an
ncreased risk of death with significantly worse survival at six
onths and further separation of the survival curve by one
ear (Fig. 1).
iabetic patients enrolled in the REPLACE-2 trial. Table
describes the characteristics of the diabetic patients
andomized to the two treatment arms. There were no
ifferences in any of the baseline demographic, clinical, or
rocedural characteristics between the two groups. Provi-
ional GP IIb/IIIa inhibition was used in 36 (4.6%) patients
andomized to the routine GP IIb/IIIa arm, compared with
5 (7.7%) patients in the bivalirudin arm (p  0.009).
mong these 65 patients, there was a high incidence of
eath (2, 3.1%), myocardial infarction (7, 10.8%), urgent
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Diabetic Patients in the REPLACE-2 Trial June 21, 2005:1932–8evascularization (2, 3.1%), and major bleeding (5, 7.7%).
igure 2 shows the early and long-term outcomes of the
iabetic and non-diabetic patients enrolled in the two arms.
pecifically, there was no difference in the incidence of early
eath, myocardial infarction, urgent revascularization, or
ny of the composite end points. There was no significant
ifference in the six-month incidence of target vessel revas-
ularization in diabetic patients randomized to bivalirudin
ompared with those treated with GP IIb/IIIa inhibitors
Table 1. Baseline and Procedural Characteristi
Non-D
Age, yrs (mean  SD)
Age 75 yrs 5
Weight, kg
(mean  SD)
Creatinine clearance, ml/min
(mean  SD)
Women 1,0
Caucasian 4,1
Prior MI 1,5
Prior PCI 1,4
Prior CABG 7
Smoking within the last year 1,2
Hypertension 2,6
Congestive heart failure 2
History of stroke
Procedure type
Stent 3,7
Atherectomy 1
Balloon only 3
Multivessel intervention attempted 6
Target vessel (not mutually exclusive)
Left anterior descending 1,8
Left circumflex 1,1
Right coronary artery 1,5
Left main
Bypass graft 2
Thienopyridine pretreatment 3,7
Median ACT, s (heparin  routine
GP IIb/IIIa arm)
ACT  activated clotting time; CABG  coronary artery b
 percutaneous coronary intervention.
Table 2. Outcomes of Non-Diabetic Patients C
Non
(n
Death at 30 days 13
MI at 30 days 305
Death/MI at 30 days 310
Urgent revascularization at 30 days 63
Urgent PCI at 30 days 37
Urgent CABG at 30 days 28
Death/MI/urgent revascularization
at 30 days
344
Death at 6 months 43
Death/MI at 6 months 380
Target vessel revascularization
at 6 months
346
Death at 1 yr 79Abbreviations as in Table 1.101 [12.8%] vs. 77 [10.5%], p  0.182). At one year, there
as no significant difference in survival, with 19 (2.3%)
eaths in the bivalirudin arm versus 30 (3.9%) deaths in the
eparin and GP IIb/IIIa inhibitor arm (p  0.065) (Fig. 3).
leeding outcomes. There was no difference in the inci-
ence of major bleeding between diabetic and non-diabetic
atients (3.1% vs. 3.3%, p  0.76). There was a borderline
ignificant interaction (p 0.058) between diabetic patients
nd randomized treatment with respect to bleeding. Among
the Patients Based on Diabetic Status
c Patients
8)
Diabetic Patients
(1,624) p Value
11 63  10 0.001
3.1%) 233 (14.3%) 0.19
17 93  20 0.001
34 99  43 0.06
4%) 484 (29.8%) 0.001
3.9%) 1,443 (88.9%) 0.001
6.9%) 593 (37.4%) 0.73
3.7%) 615 (38.2%) 0.001
6.7%) 370 (22.8%) 0.001
9.3%) 304 (19.2%) 0.001
1.8%) 1,309 (80.8%) 0.001
.3%) 182 (11.3%) 0.001
.2%) 45 (2.8%) 0.19
5.5%) 1,383 (85.2%) 0.75
.6%) 69 (4.2%) 0.25
.4%) 123 (7.6%) 0.81
5.4%) 285 (17.8) 0.03
2.4%) 652 (40.1%) 0.12
7.4) 507 (31.2%) 0.004
5.4%) 537 (33.1%) 0.09
.1%) 24 (1.5%) 0.23
.3%) 119 (7.3%) 0.004
5.3%) 1,426 (87.1%) 0.01
356 0.48
raft; GP  glycoprotein; MI  myocardial infarction; PCI
pared With Diabetic Patients
betic
68)
Diabetic
(n  1,624) p Value
0%) 6 (0.37%) 0.66
2%) 91 (5.62%) 0.05
2%) 91 (5.62%) 0.03
5%) 16 (0.99%) 0.16
5%) 14 (0.86%) 0.96
4%) 2 (0.12%) 0.01
0%) 94 (5.80%) 0.005
9%) 29 (1.79%) 0.012
1%) 131 (8.18%) 0.40
%) 182 (11.2%) 0.001
5%) 49 (3.06%) 0.004cs of
iabeti
(4,36
62 
71 (1
85 
93 
48 (2
02 (9
89 (3
69 (3
29 (1
50 (2
87 (6
32 (5
96 (2
34 (8
58 (3
23 (7
62 (1
51 (4
98 (2
47 (3
48 (1
33 (5
25 (8
349om
-Dia
 4,3
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June 21, 2005:1932–8 Diabetic Patients in the REPLACE-2 Trialhe diabetic patients, major bleeding was seen in 25 (3.0%)
f patients randomized to the bivalirudin arm and 26 (3.3%)
f those randomized to the GP IIb/IIIa inhibitor arm (p 
.69), whereas among the non-diabetic patients, this oc-
urred in 2.14% in the bivalirudin arm versus 4.42% in the
P IIb/IIIa inhibitor arm (p  0.001). There was less
igure 1. Survival of the cohort at one year based on diabetes status. Solid
ine  non-diabetic patients; dashed line  diabetic patients.
Table 3. Baseline and Procedural Characteristi
Randomization Arm
Hep
GP I
Age, yrs (mean  SD)
Age 75 yrs
Weight, kg (mean  SD)
Creatinine clearance, ml/min
(mean  SD)
Women
Caucasian
Anti-diabetes treatment
Diet only
Thiazolidinedione
Sulfonylurea/metformin
Sulfonylurea/metformin 
thiazolidinedione
Insulin
Insulin  oral
Others
Prior MI
Prior PCI
Prior CABG
Smoking within the last year
Hypertension
Congestive heart failure
History of stroke
Procedure type
Stent
Atherectomy
Balloon only
Multivessel intervention attempted
Target vessel (not mutually exclusive)
Left anterior descending
Left circumflex
Right coronary artery
Left main
Bypass graft
Thienopyridine pretreatmentAbbreviations as in Table 1.inor bleeding in the bivalirudin arm in both diabetic
24.4% vs. 12.6%, p  0.001) and non-diabetic (26.0% vs.
3.6%, p  0.001) patients. The need for blood transfusion
as low in both arms, with only 17 diabetic patients (2.2%)
ndergoing transfusion in the heparin and GP IIb/IIIa arm,
ompared with 20 (2.4%) in the bivalirudin arm (p  0.77).
hrombocytopenia was less common in the bivalirudin arm
0.6% vs. 2.0%, p  0.016)
ISCUSSION
ur data corroborate and extend findings from previous
tudies showing that compared with non-diabetic patients,
iabetic patients have a similar short-term outcome after
ontemporary PCI but a markedly exaggerated long-term
ortality risk. In the REPLACE-2 trial, compared with
on-diabetic patients the diabetic cohort had no difference
n early outcome, whereas the one-year mortality was
ignificantly elevated. However, in parallel with the main
rial, among the diabetic patients, there was no difference in
the Diabetic Patients Based on the
 Platelet
Ia Inhibitor
784)
Bivalirudin
(n  840) p Value
10 64  10 0.61
15.4%) 112 (13.3%) 0.23
20 93  20 0.75
43 100  43 0.13
30.7%) 243 (28.9%) 0.43
89.3%) 743 (88.5%) 0.59
0.54
12.0%) 78 (9.3%)
4.0%) 39 (4.6%)
46.4%) 385 (45.8%)
6.1%) 65 (7.7%)
15.1%) 121 (14.4%)
11.2%) 104 (12.4%)
5.3%) 48 (5.7%)
36.9%) 310 (37.9%) 0.67
37.1%) 326 (39.1%) 0.41
23.1%) 189 (22.65) 0.79
19.2%) 157 (19.1%) 0.96
82.0%) 666 (79.6%) 0.21
11.1%) 96 (11.6%) 0.76
2.4%) 26 (3.1%) 0.41
86.15) 708 (84.3%) 0.31
4.1) 38 (4.5%) 0.57
7.3%) 66 (7.9%) 0.66
16.6%) 157 (19.0%) 0.21
39.8%) 340 (40.5%) 0.78
31.3%) 262 (31.2%) 0.98
32.7%) 281 (33.5%) 0.73
1.7%) 11 (1.3%) 0.56
7.0%) 64 (7.6%) 0.64
87.5%) 741 (88.3%) 0.61cs of
arin
Ib/II
(n 
64 
121 (
93 
98 
241 (
700 (
94 (
31 (
364 (
48 (
118 (
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147 (
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Diabetic Patients in the REPLACE-2 Trial June 21, 2005:1932–8schemic events, need for revascularization, or one-year
urvival among those randomized to receive bivalirudin and
rovisional GP IIb/IIIa inhibitor versus those randomized
o heparin and routine GP IIb/IIIa inhibitor.
Multiple studies have shown a worse outcome among
iabetic patients after myocardial infarction (5), unstable
ngina (6,7), and coronary bypass grafting (8–10). Diabetic
atients undergoing PCI seem to have a similar short-term
utcome compared with non-diabetic patients, but have an
ncreased risk of subsequent myocardial infarction, resteno-
is, and mortality (11). Indeed the Bypass Angioplasty
evascularization Investigation (BARI) trial showed better
urvival in patients randomized to coronary artery bypass
rafting compared with those undergoing PCI (12). These
ndings were, however, not replicated in the BARI trial
egistry (13) and other studies (10) suggesting that PCI may
e a viable revascularization strategy in carefully selected
iabetic patients.
Multiple studies have focused on the short- and long-
erm outcomes of PCI among diabetic patients treated using
ontemporary techniques. In a study of 689 patients under-
oing multivessel stenting at a single center, although there
as no difference in the incidence of in-hospital death or
yocardial infarction, the risk of target lesion revasculariza-
ion or long-term mortality was significantly higher in
iabetic patients (11). Similarly, data from the National
eart, Lung, and Blood Institute Dynamic registry de-
cribed an almost two-fold increase in the risk of long-term
ortality among diabetic patients compared with non-
iabetic patients (14). Retrospective analysis from other
arge clinical trials replicates these findings. In the Preven-
ion of Restenosis With Tranilast and Its Outcomes
PRESTO) trial, compared with the 8,798 non-diabetic
atients, diabetic patients (n  2,694) were more likely to
ave worse clinical and angiographic characteristics, al-
hough this risk profile did not translate into any apparent
ncrease in short-term complications (15). Diabetic patients
igure 2. Outcomes of diabetic and non-diabetic patients by randomiza-
ion arm. CI  confidence interval; GP  glycoprotein; Hep  heparin;
I  myocardial infarction.ere, however, more likely to have new lesions, to have
l
progression of previous lesions, or to die by nine months
2.1% vs. 0.9%).
Against this backdrop, the role of platelet GP IIb/IIIa
nhibitors among diabetic patients undergoing PCI has
ndergone much scrutiny after publication of the combined
nalysis of the three trials of abciximab (3). In that study of
,262 diabetic patients, use of abciximab was associated with
reduction in mortality from 4.5% to 2.5% (p  0.031).
urthermore, in the diabetic substudy of the Evaluation of
latelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT)
t six months, abciximab therapy was associated with a
eduction in target vessel revascularization or the composite
f death and myocardial infarction (16). The effects of
bciximab on restenosis, however, could not be confirmed
mong the overall cohort of patients in the Evaluation of
eoPro and Stenting to Eliminate Restenosis (ERASER)
rial (17) nor among diabetic patients in the Diabetes
bciximab Stent Evaluation (DANTE) study (18). Further
upport for the survival advantage of GP IIb/IIIa inhibitors
ame from a meta-analysis of six large trials that showed a
ignificant mortality reduction with use of intravenous GP
Ib/IIIa among diabetic patients with acute coronary syn-
romes (2). Among the 1,279 diabetic patients undergoing
CI during index hospitalization, the mortality rate was
educed from 4.0% to 1.2% (p  0.002) with the use of GP
Ib/IIIa inhibitors. Based on these data, the use of GP
Ib/IIIa inhibitors had been advocated in all diabetic pa-
ients undergoing PCI (19,20). Recently, this hypothesis
as directly tested in the Is Abciximab a Superior Way to
liminate Elevated Thrombotic Risk in Diabetics (ISAR-
WEET) study (21). Among the 701 diabetic patients
ndergoing elective PCI after pre-loading with clopidogrel,
o difference in either peri-procedural death, myocardial
nfarction, or urgent revascularization or in the primary end
oint of death and myocardial infarction at one year (8.3%
s. 8.6%, p  0.91) was noted among patients randomized
o abciximab or placebo. Although the study has been
riticized for being underpowered, it remains the only direct
est of GP IIb/IIIa inhibitors in this population (22).
The REPLACE-2 trial showed the non-inferiority of a
trategy of bivalirudin with provisional GP IIb/IIIa inhibi-
ors when compared with heparin plus routine GP IIb/IIIa
nhibitors in a broad spectrum of patients undergoing PCI.
igure 3. Survival of the diabetic patients by randomization arm. Solid
ine  bivalirudin; dashed line  glycoprotein IIb/IIIa inhibitor. PCI 
ercutaneous coronary intervention.
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June 21, 2005:1932–8 Diabetic Patients in the REPLACE-2 Trialiven the apparent extraordinary benefit of GP IIb/IIIa
lockade among diabetic patients, however, this subgroup
eserves particular scrutiny. Our study provides reassuring
ata regarding the efficacy of the bivalirudin anticoagulant
trategy among diabetic patients undergoing PCI. Not only
as there no difference in short-term outcome among
iabetic patients randomized to the two arms, but also the
atients treated with bivalirudin had numerically better
although statistically non-significant) survival by 1-year
ollow-up. The number of patients in our analysis (n 
,624) was similar to that in the prior analysis by Bhatt et al.
3) (n  1,462) of abciximab, and the one-year mortality
ith the bivalirudin-based strategy (2.28%) or in the GP
Ib/IIIa inhibitor arm (3.9%) is also comparable with that
een in their analysis (2.5% in the abciximab arm), or in the
ore contemporary Do Tirofiban and ReoPro Give Similar
fficacy Outcomes (TARGET) trial (2.1% in the tirofiban
roup and 2.9% in the abciximab group) (23). Although not
efinitive, the relatively large size of our cohort suggests that
ur findings are likely to be extant.
The biological basis of a long-term protective effect of a
trategy of GP IIb/IIIa inhibition in diabetic patients has
ever been fully elucidated. Hypothesized mechanisms have
ncluded plaque stabilization, suppression of inflammatory
ediators, reduced distal embolization, and an assuaged
nflammatory response to vascular injury (24). Given that
here are no data regarding whether bivalirudin as a direct
hrombin inhibitor has these effects, the similar outcome
ith these two strategies cannot be fully explained. It is
onceivable that parallel changes in interventional tech-
iques, primary and secondary preventive measures, and
mprovements in clinical care that have occurred over the
ast decade may have diminished the additional long-term
urvival benefit of routine GP IIb/IIIa inhibition. However,
t is equally plausible that a strategy of bivalirudin with
rovisional GP IIb/IIIa inhibition provides an analogous
rotective effect on the PCI site, thus explaining the similar
urvival in the two arms. However, these hypotheses have
ever been tested and need further investigation to support
r refute them.
We did not find any reduction in major bleeding or the
eed for transfusion among diabetic patients treated with
ivalirudin. This may relate to the small number of events
nd the lack of statistical power or may be a spurious finding
iven the relatively weak interaction in the setting of a
econdary analysis. The incidence of major bleeding in the
ivalirudin arm was similar among diabetic and non-
iabetic patients, and was markedly higher among non-
iabetic patients treated with GP IIb/IIIa inhibitors. Any
onclusion from such data, however, needs to be made
autiously because such a protective interaction between
iabetes and risk of bleeding with GP IIb/IIIa inhibitors has
ever been previously described.
Our results are based on a retrospective analysis of
rospectively collected data and thus are prone to the
imitations inherent to such studies. Further patients withT-segment elevation myocardial infarction and non–ST-
egment elevation myocardial infarction with ongoing isch-
mia were excluded from the REPLACE-2 trial and,
herefore, our findings cannot be extended to this cohort.
ata on glycemic control were not available. The small
umber of events combined with multiple anti-diabetes
egimens prohibits a study of association of anti-diabetes
herapy with short- or long-term end points. Our study was
ot powered to show either superiority or non-inferiority of
ne versus the other strategy in diabetic patients. However,
iven that the number of diabetic patients or events in our
nalysis is larger than in the previous analysis from the GP
Ib/IIIa inhibitor trials, our data provide reassurance that
he strategy of bivalirudin with provisional GP IIb/IIIa
nhibitors does not carry any relevant mortality hazard.
iven the reduction in bleeding events (albeit minor),
horter duration of infusion, and cost factors, it is likely that
large number of diabetic patients would be treated with
ivalirudin and these data should serve to provide some
vidence base for a clinician contemplating such a strategy.
ONCLUSIONS
iabetes remains a major health care challenge, and there is
worse long-term survival rate among diabetic patients
ndergoing PCI. The strategy of using bivalirudin with
rovisional GP IIb/IIIa inhibition in diabetic patients is as
ffective as the combination of heparin plus routine GP
Ib/IIIa blockade.
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